Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 124 people in total — 60 received an inhaled form of the antibiotic ciprofloxacin (called Ciprofloxacin Inhale or BAYQ3939) and 64 received a placebo (an inactive inhaled treatment). The trial was primarily measuring how much the amount of bacteria in participants' sputum (mucus coughed up from the lungs) changed after 29 days of treatment. It also tracked a range of secondary measures, including lung function, how long it took before participants needed antibiotic treatment for a flare-up of their condition, and self-reported quality of life. The reported data shows that, for the primary outcome — change in bacterial load in sputum — the ciprofloxacin inhale group had an average reduction of 2.94 units (measured on a logarithmic scale, which is a way of expressing very large or small numbers more simply) compared to a reduction of 0.32 units in the placebo group. For the secondary lung function measures (how much air participants could breathe out), the reported changes from baseline were small in both groups across multiple time points, with figures generally close to zero in both directions. The time-to-flare-up data was reported as "not available" in the submitted results. For self-reported quality of life, the reported scores on both questionnaires were broadly similar between the two groups across the measurement time points, with no large numerical differences noted in the data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 23018904) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Cystic Fibrosis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been officially diagnosed with bronchiectasis (a lung condition where the airways are permanently widened) that is either of unknown cause or happened after a lung infection, and is not related to cystic fibrosis.
- Your lung condition has been stable and your treatment routine has not changed for at least the past 30 days.
Who may not be able to join:
- Your lung function test results (specifically a breathing test called FEV1) show that your lungs are either severely limited (below 35% of expected) or only mildly affected (above 80% of expected) (confirm with trial site).
- You have a condition called allergic bronchopulmonary aspergillosis, which is a lung allergy reaction to a specific type of fungus.
- You have an immune system condition that requires you to receive regular immunoglobulin (antibody) replacement treatment.
- You have an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bayer Study Director, Bayer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Total Bacterial Load in the Sputum at End of Treatment (Day 29).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.